Cited 73 times in
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.